Skip to main content

Harvard Bio to Cut Staff at Genomic Solutions UK Operations

NEW YORK, June 7 (GenomeWeb News) - Harvard Bioscience plans to eliminate certain jobs at the Huntingdon, UKfacility of its Genomic Solutions subsidiary, according to an 8-K filed with the US Securities and Exchange Commission.


In the filing, Harvard Bioscience said that it will reorganize, consolidate, and eliminate certain activities at the facility. Part of the reorganization includes relocating some activities to the firm's Holliston, Mass., facilities.


According to Harvard Bio, "this will result in the elimination of a number of employee positions."


The firm expects to take second-quarter charges of $600,000 to $800,000 related to severance and benefits and charges of $100,000 to $300,000 related to lease terminations.


Genomic Solutions is part of Harvard Bio's capital equipment business, which the firm last August said it plans to divest. At that time, Harvard Bio said it expected to complete the divestiture or sale within one year.


According to the most recent filing, Harvard Bio is continuing its efforts to divest the capital equipment business. The firm said it would kill the reorganization plan if it sells the business "prior to our completion of all activities under this plan."

The Scan

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.